INJ Search

CLOSE


Int Neurourol J > Volume 30(3); 2026 > Article
Kim, Song, Lee, and Song: Serotonergic Transmission in the Hippocampus Is Subject to Multifaceted Modulation by Other Neurotransmitters

ABSTRACT

Purpose

Serotonin (5-HT) release in the hippocampus is modulated by N-methyl-D-aspartate (NMDA) receptor activity, particularly under hypoxic conditions, but the roles of other neurotransmitter systems remain unclear. This study examined how several neurotransmitters affect spontaneous 5-HT release in rat hippocampal slices and whether these effects are direct or interneuron-mediated.

Methods

Rat hippocampal slices (400 μm) were preloaded with [3H]5-HT and superfused with oxygenated buffer. Acetylcholine (ACh), norepinephrine (NE), dopamine (DA), NMDA, γ-aminobutyric acid (GABA), glycine, or neuropeptide Y (NPY) were applied for 20 minutes, and [3H]5-HT release was measured in 10-minute fractions. Tetrodotoxin (TTX) was used in parallel experiments to block action potential-dependent neurotransmission.

Results

In control slices, spontaneous [3H]5-HT release reached a stable baseline after approximately 50 minutes of superfusion. ACh (10-5M), GABA (10-5M), glycine (10-5M), and NPY (10-6M) did not significantly affect 5-HT release relative to control. In contrast, NE (10-5M) and DA (10-5M) significantly increased 5-HT release (peaking at ~15%–37% above baseline, P<0.05), and these effects persisted in the presence of TTX, suggesting a direct action on serotonergic terminals. NMDA (10-4M) also transiently enhanced 5-HT release (~22% above baseline, P<0.05), but this effect was completely abolished by TTX, indicating reliance on interneuronal activity.

Conclusions

Hippocampal 5-HT release is differentially regulated by neurotransmitter systems: NE and DA act directly at serotonergic terminals, whereas NMDA’s effect requires interneuronal activity. These findings highlight complex neurochemical interactions that may underlie serotonergic modulation in neuropsychiatric disorders.

• HIGHLIGHTS

- Rat hippocampal slices revealed transmitter-specific regulation of serotonin release. Norepinephrine and dopamine significantly enhanced serotonin (5-HT) release, and their effects persisted during tetrodotoxin exposure, indicating direct actions at serotonergicterminals. N-methyl-D-aspartate transiently increased 5-HT release, but tetrodotoxin abolished thisresponse, supporting an interneuron-dependent mechanism. Acetylcholine, gamma-aminobutyric acid, glycine, and neuropeptide Y produced no significant effects under the testedconditions.

INTRODUCTION

The hippocampal slice is a well-established in vitro model that preserves much of the native synaptic circuitry and allows precise control of experimental conditions [1, 2]. The hippocampus receives dense innervation from several neurotransmitter systems, including noradrenergic fibers from the locus coeruleus [3-9], serotonergic projections from the raphe nuclei [1, 10-12], dopaminergic inputs from the ventral tegmental area [13-15], and cholinergic, gamma-aminobutyric acid (GABA)ergic, and glutamatergic projections from the medial septal nucleus [16, 17]. Neuropeptide Y (NPY)-containing interneurons are also widely distributed in the hippocampal formation [18]. Despite this well-defined anatomy, functional interactions between these systems and hippocampal serotonergic signaling remain incompletely understood.
Previous studies have shown that neurotransmitters can regulate serotonin (5-HT) release through both direct and indirect mechanisms. For example, glutamate acting on N-methyl-Daspartate (NMDA) receptors can suppress serotonergic output via GABAergic interneurons [19], while α2-adrenoceptor activation reduces hippocampal 5-HT release, indicating a facilitatory role for basal noradrenergic tone [20, 21]. Other heteroreceptors, such as μ-opioid receptors, can inhibit 5-HT release [22], whereas 5-HT itself modulates other transmitter systems, including acetylcholine (ACh) [23], noradrenaline [24], and GABA [25]. These findings highlight the bidirectional nature of neurotransmitter crosstalk in the hippocampus.
Neuromodulatory interactions are particularly relevant under pathological conditions. During ischemia or hypoxia, multiple neurotransmitters are dysregulated. Cerebral ischemia causes excessive glutamate release, leading to excitotoxic injury, and this has been identified as a key mechanism of ischemic hippocampal damage [26-34]. Serotonin is also massively released during ischemia, and extracellular 5-HT has been implicated in postischemic neuronal injury such as edema and delayed cell death [35]. Norepinephrine (NE) and dopamine (DA) are likewise released in ischemic or hypoxic conditions [36, 37], and these amines may play roles in injury modulation. Notably, exogenous NE administration can reduce ischemia-induced hippocampal damage, suggesting a neuroprotective role of noradrenergic activation [38]. DA release during ischemia has been associated with regional differences in vulnerability to injury [39]. Moreover, activation of excitatory amino acid (glutamate) receptors can influence the release of other transmitters such as ACh in the hippocampus [40]. These observations hint that multiple transmitter systems can influence each other’s release under stress conditions, and that 5-HT release in the hippocampus might be subject to a network of regulatory influences beyond just glutamate/NMDA-mediated effects.
Given this background, we aimed to clarify how various neurotransmitters influence spontaneous 5-HT release in the hippocampus, using an in vitro slice model under controlled conditions. The lower urinary tract is thought to be centrally regulated by different neurotransmitters. The spinal and supraspinal reflex pathways controlling the bladder and external urethral sphincter are dependent on the neurotransmitter glutamate, DA, and ACh. Tonic suppressive regulation is provided by inhibitory amino acids GABA and glycine within the pontine micturition center, modulating the capacity of the bladder [41-43]. A major neurotransmitter that blocks central control is serotonin. The gradual filling of the bladder is usually accompanied by the activation of the subcortical network, including the periaqueductal gray and parahippocampal cortex [44, 45].
We have previously reported a study that serotonin discharge is regulated by many neurotransmitters of rat hippocampus associated with the continence central circuit [46]. However, a neuropharmacological interpretation was not addressed.
Serotonergic neurotransmission plays a central inhibitory role in the control of lower urinary tract function. Activation of central serotonergic pathways suppresses parasympathetic excitatory input to the urinary bladder and modulates urethral sphincter activity through spinal and supraspinal mechanisms. Supraspinal circuits involving the periaqueductal gray, pontine micturition center, hypothalamus, and parahippocampal cortex integrate emotional, cognitive, and visceral inputs to regulate continence. Although serotonergic projections to the hippocampus have traditionally been studied in the context of cognition and affect, emerging evidence suggests that hippocampal and parahippocampal regions participate in central continence networks by providing contextual and safety-related signals during bladder filling. Previous studies demonstrated that NMDA receptor activation enhances hippocampal 5-HT release via interneuron-dependent mechanisms; however, it has remained unknown whether other neurotransmitters modulate serotonergic output directly at nerve terminals or indirectly via local circuits. This represents a critical gap in understanding how polypharmacological agents may influence central continence control through serotonergic pathways [41, 44-48].
In the present study, we aimed to provide such an interpretation, demonstrating that serotonergic transmission in the hippocampus is subject to multifaceted modulation by other neurotransmitters. We focused on neurotransmitters representing major hippocampal inputs: ACh, NE, DA, an NMDA-type excitatory amino acid agonist, the inhibitory amino acids GABA and glycine, and the NPY. By applying these agents to rat hippocampal slices preloaded with [3H]5-hydroxytryptamine ([3H]5-HT), we quantified changes in 5-HT release. To discern whether the effects are direct (on 5-HT nerve terminals) or indirect (mediated by interneurons or network activity), we performed parallel experiments in the presence of tetrodotoxin (TTX) to block action potential propagation. We hypothesized that if a neurotransmitter’s effect on 5-HT release is suppressed by TTX, it likely operates via activation of intermediate neurons (polysynaptic mechanism), whereas an effect persisting in TTX indicates a direct action on 5-HT terminals (heteroreceptor mechanism) [41, 44-48].
The distinction between direct monoaminergic modulation and interneuron-dependent glutamatergic modulation of hippocampal serotonin release has implications for supraspinal control of micturition. Serotonergic pathways exert tonic inhibitory control over bladder reflexes, and differential modes of modulation may influence continence under physiological and pharmacological conditions. These findings should be interpreted as mechanistic and hypothesis-generating, as they are derived from an in vitro hippocampal slice model.
By elucidating these mechanisms, our study seeks to deepen understanding of serotonergic modulation in the hippocampus. Such insights have implications for neuropsychiatric pharmacology, as the hippocampus is a key brain region involved in mood regulation, stress responses, and cognition, and is a target for drugs acting on monoaminergic and other neurotransmitter systems.

MATERIALS AND METHODS

Animals and Slice Preparation

Male Sprague-Dawley rats (150–200 g) were used in this study and were bred in-house under standard housing conditions. Following decapitation, the brains were rapidly removed, and both hippocampi were carefully dissected on ice. Transverse hippocampal slices, each 400 μm thick, were prepared using a McIlwain tissue chopper and immediately transferred to cold artificial cerebrospinal fluid (ACSF) for recovery. The ACSF contained 124mM NaCl, 4mM KCl, 2mM CaCl2, 1mM MgSO4, 1.25mM KH2PO4, 25mM NaHCO3, and 10mM glucose, adjusted to pH 7.4 and continuously bubbled with 95% O2/5% CO2 to maintain oxygenation. To inhibit 5-HT metabolism during the experiments, the monoamine oxidase inhibitor nialamide (12.5 μM) was included in the buffer.

[3H]5-HT Uptake and Release Assay

To stabilize the tissue, slices were first preincubated in oxygenated ACSF at 37°C for 30 minutes. They were then incubated for 20 minutes in ACSF containing [3H]5-HT creatinine sulfate (specific activity 20 Ci/mmol, 0.1 μM; Amersham) to allow radiolabeled 5-HT uptake into serotonergic nerve terminals. After the uptake phase, slices were washed with fresh ACSF to remove unincorporated tracer. Six slices (obtained from 3 rats, 2 slices per hippocampus) were randomly assigned to 6 superfusion chambers (1 slice per 3-mL chamber). Superfusion was carried out at 37°C with ACSF at a flow rate of approximately 0.3 mL/min in a shaking water bath to ensure gentle agitation. To block reuptake of released 5-HT, the selective 5-HT uptake inhibitor zimelidine (10 μM) was included in the perfusion medium from the onset of superfusion. The perfusate was collected and replaced with fresh buffer at 10-minute intervals, yielding sequential fractions for [3H]5-HT release measurement.

Drug Treatments

Once a stable baseline release was established, neurotransmitters of interest were introduced to the superfusion chambers to examine their effects on [3H]5-HT release. Pilot time-course experiments had shown that spontaneous release stabilized after approximately 50 minutes of superfusion, so drug administration was initiated at 60 minutes. Each drug was applied for a 20-minute period (from 60 minutes to 80 minutes) unless specified otherwise. Experimental conditions included: Control (No transmitter added (baseline release monitored); TTX alone (1μM TTX applied from 0–100 minutes to assess the effect of blocking action potentials on basal release); ACh (10–5M, applied 60–80 minutes); NE (10–5M, applied 60–80 minutes); DA (10–5M, applied 60–80 minutes); NMDA (10–4M, applied 60–80 minutes); GABA (10–5M, applied 60–80 minutes); glycine (10–5M, applied 60–80 minutes); NPY (10–6M, applied 60–80 minutes).
For each transmitter group, a corresponding TTX-pretreated group was run in parallel. In these groups, TTX (1 μM; Sigma, USA) was added from the beginning of superfusion (0 minute) and maintained throughout the experiment, and the neurotransmitter was applied at 60–80 minutes under the same conditions. This design allowed direct comparison of transmitter effects in the presence or absence of action potential-dependent synaptic transmission. The concentrations of neurotransmitters (10–5M–10–4M) were selected based on prior hippocampal slice and superfusion studies, in which micromolar concentrations are routinely required to achieve effective receptor activation due to diffusion barriers, enzymatic degradation, and dilution in the extracellular space [23, 25]. These concentrations have been widely accepted as functionally relevant in vitro and do not imply equivalent extracellular levels in vivo.

Measurement of [3H]5-HT Release

At the conclusion of the 100-minute experiment, slices were removed from the chambers and solubilized in 1 mL of Soluene-350 (Packard) for 2 hours to extract residual [3H] content. Subsequently, 50 μL of glacial acetic acid was added to neutralize the lysate. Radioactivity in each 10-minure perfusate fraction (1-mL aliquot from the 3 mL collected) and in the tissue lysate was quantified by liquid scintillation counting (Beckman scintillation counter) following addition of 9-mL scintillation cocktail (Beckman Ready Safe). The disintegrations per minute of all fractions plus the lysate were summed to represent the total [3H] uptake per slice. The release for each fraction was then expressed as a percentage of this total uptake (fractional release). For data presentation, release measured at 50 minutes (just prior to drug administration) was defined as 100%, and subsequent values were normalized relative to this baseline.

Data Analysis

Results are reported as mean±standard error of the mean for each experimental group. Statistical analysis was performed using analysis of variance (ANOVA) to compare release profiles across treatment groups (e.g., control vs. drug, ±TTX). Where ANOVA showed a significant effect, Scheffé post hoc test was applied for pairwise comparisons. A P-value <0.05 was considered statistically significant.

RESULTS

Baseline Serotonin Release and Effect of TTX

In control (untreated) hippocampal slices, [3H]5-HT exhibited a high initial efflux that gradually declined over the first 30–40 minutes of superfusion. In slices continuously treated with TTX alone (without any additional neurotransmitters), a similar pattern was observed: both the time course and magnitude of spontaneous 5-HT release were comparable to controls. The cumulative spontaneous efflux over 100 minutes in TTX-treated slices did not differ significantly from untreated slices, indicating that blockade of action potentials had no appreciable effect on basal 5-HT release (Fig. 1).

Effect of NE

Application of NE (10–5M) significantly enhanced 5-HT release from hippocampal slices. As shown in Fig. 2A, during NE perfusion, fractional 5-HT release increased to 115.7%±2.3% of baseline at 60 minutes and 105.8%±5.5% at 70 minutes, compared to ~95%–100% in control slices over the same period (P<0.05). This facilitatory effect was rapid and transient; after NE washout at 80 minutes, 5-HT release returned toward baseline, with no significant difference from controls at 80–90 minutes. In the presence of TTX, NE still induced a comparable increase in 5-HT release (114.7%±1.9% at 60 minutes, 108.5%±7.8% at 70 minutes), indicating that NE enhances serotonergic output independently of action potential-driven synaptic activity (P<0.05).

Effect of DA

DA (10–5M) produced a more pronounced increase in [3H]5-HT release than NE. During the 20 minutes application, 5-HT release rose to 130.5%±6.2% of baseline at 60 minutes and 137.1%±9.9% at 70 minutes (vs. ~95% in controls, P<0.05) (Fig. 2B). The effect of DA was sustained beyond washout: at 80 minutes, release remained elevated at 125.9%±7.5% (vs. 90.4%±0.9% in controls) and at 90 minutes, 109.2%±7.9% (vs. 87.3%±1.0% in controls), indicating a slower return to baseline after dopaminergic stimulation. In TTX-pretreated slices, DA still significantly enhanced 5-HT release (121.9%±5.2% at 60 minutes and 134.0%±9.7% at 70 minutes), closely matching the response in slices without TTX. After washout, DA+TTX slices remained above baseline (113.5%±4.3% at 80 minutes, 93.2%±10.2% at 90 minutes), confirming that DA’s facilitation of 5-HT release occurs independently of action potential propagation and likely reflects direct modulation of serotonergic terminals (P<0.05).

Effect of NMDA

NMDA (10–4M) also increased 5-HT release, but via a mechanism distinct from NE and DA. Without TTX, NMDA elevated fractional 5-HT release to 122.5%±2.4% of baseline at 60 minutes and 105.0%±3.4% at 70 minutes (P<0.05 vs. control) (Fig. 2C). However, in slices treated with TTX, NMDA failed to enhance 5-HT release: the NMDA+TTX group showed 104.7%± 0.4% at 60 minutes and 90.2%±2.8% at 70 minutes, not different from baseline and significantly lower than NMDA alone (P<0.05).

Effect of ACh

ACh (10–5M) did not significantly alter 5-HT release. During the 20-minute ACh perfusion (60–80 minutes), fractional release remained at baseline (60 minutes: 97.2%±1.6% vs. 94.9%±1.0% in controls; 70 minutes: 90.9%±3.5% vs. 92.3%±1.1% in controls; not significant) (Fig. 3A).

Effect of GABA, Glycine, and NPY

Application of the inhibitory amino acids GABA (10–5M) and glycine (10–5M), as well as the neuromodulator NPY (10–6M), produced no significant changes in 5-HT release. For GABA, release at 60 minutes and 70 minutes was 97.7%±0.5% and 91.2%±3.0%, respectively, similar to controls (94.9%±1.0% and 92.3%±1.1%) (Fig. 3B). Glycine perfusion yielded 97.9%±1.3% at 60 minutes and 92.1%±0.9% at 70 minutes (Fig. 3C), while NPY resulted in 92.9%±2.5% at 60 minutes and 86.8%±2.5% at 70 minutes (Fig. 3D).

DISCUSSION

In this study, we examined how various neurotransmitters modulate spontaneous 5-HT release from hippocampal slices. Our results reveal distinct modes of serotonergic regulation. The monoamines NE and DA strongly enhanced 5-HT release via direct receptor-mediated actions at 5-HT terminals, as these effects persisted in the presence of TTX, indicating independence from action potential-driven network activity. In contrast, NMDA increased 5-HT release only when synaptic transmission was intact, and the effect was abolished by TTX, suggesting an indirect, interneuron-mediated mechanism. ACh, inhibitory amino acids GABA and glycine, and NPY did not acutely alter 5-HT release, indicating limited direct modulation of serotonergic terminals (Figs. 2 and 3).
The distinction between direct terminal modulation (NE, DA) and interneuron-dependent modulation (NMDA) has important implications for neurourology. Serotonergic pathways exert tonic inhibitory control over micturition reflexes, and differential mechanisms of modulation may influence how central neurotransmitter systems shape continence under physiological and pharmacological conditions.
Direct facilitation of hippocampal 5-HT release by NE and DA suggests that increased monoaminergic tone—such as during stress, arousal, or antidepressant therapy—may enhance serotonergic signaling independently of network firing. In contrast, glutamatergic modulation via NMDA receptors requires intact interneuronal circuits, highlighting a context-dependent mechanism that may become prominent during heightened network activity such as ischemia, seizures, or emotional stress.
Importantly, the present findings are derived from an in vitro hippocampal slice model and do not directly address in vivo voiding behavior. Therefore, conclusions regarding functional effects on micturition should be interpreted as mechanistic and hypothesis-generating. Future in vivo studies combining behavioral urodynamic assessment with neurochemical measurements will be necessary to establish causal links between hippocampal serotonergic modulation and lower urinary tract function [41, 44-48].
NE markedly increased 5-HT release, an effect unaffected by TTX, supporting direct action on serotonergic terminals or TTX-insensitive mechanisms. Previous studies show that manipulation of noradrenergic receptors alters hippocampal 5-HT output [20, 21, 47]. Our data provide direct evidence that NE facilitates 5-HT release, likely via excitatory adrenergic receptors on 5-HT terminals, consistent with the proposed mechanism of serotonin norepinephrine reuptake inhibitors.
DA similarly produced a strong, sustained enhancement of 5-HT release independent of network activity. The hippocampus receives dopaminergic input from the ventral tegmental area [13-15], and DA clearance partly occurs via the NE transporter [6], reflecting close monoamine interplay. This direct dopaminergic facilitation may affect hippocampal signaling during stress or novelty and may contribute to the neuromodulatory effects of drugs like bupropion.
NMDA receptor activation enhanced 5-HT release in an activity-dependent manner (Fig. 2C). In the presence of TTX, the effect was abolished, indicating an indirect mechanism via local glutamatergic interneurons or network disinhibition. Such polysynaptic facilitation may explain increased 5-HT during pathophysiological conditions, including ischemia and seizures [26-35].
ACh did not affect 5-HT release (Fig. 3A), suggesting hippocampal 5-HT terminals lack functionally coupled cholinergic receptors. Similarly, GABA, glycine, and NPY had no measurable effect (Fig. 3B–D), indicating that inhibitory or modulatory interneurons do not tonically regulate serotonergic terminal output under these conditions [18, 19, 23, 25].
Overall, hippocampal 5-HT release is modulated via 2 main pathways: direct facilitation by monoamines (NE, DA) at heteroreceptors on 5-HT terminals, and indirect, network-mediated facilitation by glutamatergic input (NMDA). This suggests that monoaminergic activity during arousal, stress, or novelty can upregulate 5-HT release, while glutamatergic activity recruits serotonergic signaling via interneuronal circuits. These interactions may be relevant for neuromodulatory processes, antidepressant mechanisms, and the actions of drugs targeting multiple neurotransmitter systems [6, 19, 21, 24, 33-35].
Our findings extend prior work on monoamine-serotonin interactions, showing that NE can facilitate local 5-HT release independently of spiking activity, and that DA similarly exerts a direct effect on serotonergic terminals. In contrast, ACh, GABA, glycine, and NPY do not acutely modulate 5-HT release, highlighting the specificity of terminal-level heterosynaptic regulation. While our in vitro slice model lacks inputs from other brain regions and systemic modulators, it provides a controlled platform for distinguishing direct versus indirect modulation of hippocampal 5-HT output. Future studies should investigate receptor subtypes mediating NE and DA effects, the interneurons mediating NMDA facilitation, and how these interactions operate in vivo under physiological and pathophysiological conditions.
In conclusion, using rat hippocampal slices, we found that spontaneous 5-HT release is differentially regulated by neurotransmitters. NE and DA directly enhance 5-HT release at serotonergic terminals, whereas NMDA increases release indirectly via interneuronal circuits. ACh, GABA, glycine, and NPY had no acute effect, indicating limited terminal-level modulation by these systems.
These results highlight selective crosstalk in the hippocampus, with monoaminergic and glutamatergic systems actively modulating serotonergic output. Direct facilitation by NE and DA may influence mood- and memory-related circuits and contribute to the therapeutic actions of antidepressants or psychostimulants. NMDA-mediated effects suggest glutamate-serotonin interactions could be targeted in pathophysiological conditions such as ischemia, epilepsy, or in rapid-acting antidepressant strategies. Overall, this differential modulation underscores the hippocampus’s complex integrative neurochemistry and informs multi-modal pharmacological approaches for neuropsychiatric and neurological disorders.

NOTES

Grant/Fund Support
This work was supported by a grant from the Soonchunhyang University Research Fund and by the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (RS-2024-00333544).
Research Ethics
All procedures were approved by the Institutional Animal Care and Use Committee of Soonchunhyang University College of Medicine (2019-4) and conformed to established guidelines for laboratory animal care and use.
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION STATEMENT
· Conceptualization: YSS, JHK
· Data curation: CYL
· Formal analysis: MS, JHK
· Funding acquisition: YSS
· Methodology: CYL
· Project administration: JHK
· Visualization: MS
· Writing - original draft: JHK, MS
· Writing - review & editing: MS, CYL

REFERENCES

1. Dingledine R. Brain slices. New York (NY): Plenum Press; 1984.
2. Schwartzkroin PA. Characteristics of CA1 neurons recorded intracellularly in the hippocampal in vitro slice preparation. Brain Res 1975;85:423-36. PMID: 1111846
crossref pmid
3. Kobayashi RM, Palkovits M, Kopin IJ, Jacobowitz DM. Biochemical mapping of noradrenergic nerves arising from the rat locus coeruleus. Brain Res 1974;77:269-79. PMID: 4152793
crossref pmid
4. Koda LY, Schulman JA, Bloom FE. Ultrastructural identification of noradrenergic terminals in rat hippocampus: unilateral destruction of the locus coeruleus with 6-hydroxydopamine. Brain Res 1978;145:190-5. PMID: 638778
crossref pmid
5. Lindvall O, Björklund A. The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method. Acta Physiol Scand Suppl 1974;412:1-48. PMID: 4531814
pmid
6. Loy R, Koziell DA, Lindsey JD, Moore RY. Noradrenergic innervation of the adult rat hippocampal formation. J Comp Neurol 1980;189:699-710. PMID: 7381046
crossref pmid
7. Pasquier DA, Reinoso-Suarez F. Differential efferent connections of the brain stem to the hippocampus in the cat. Brain Res 1977;120:540-8. PMID: 832140
crossref pmid
8. Segal M. Afferents to the entorhinal cortex of the rat studied by the method of retrograde transport of horseradish peroxidase. Exp Neurol 1977;57:750-65. PMID: 72679
crossref pmid
9. Swanson LW, Hartman BK. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol 1975;163:467-505. PMID: 1100685
pmid
10. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978;179:641-67. PMID: 565370
crossref pmid
11. Conrad LC, Pfaff DW. Autoradiographic tracing of nucleus accumbens efferents in the rat. Brain Res 1976;113:589-96. PMID: 953754
crossref pmid
12. Moore RY, Halaris AE. Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat. J Comp Neurol 1975;164:171-83. PMID: 52660
crossref pmid
13. Hökfelt T, Fuxe K, Johansson O, Ljungdahl A. Pharmaco-histochemical evidence of the existence of dopamine nerve terminals in the limbic cortex. Eur J Pharmacol 1974;25:108-12. PMID: 4435009
crossref pmid
14. Pohle W, Ott T, Müller-Welde P. Identification of neurons of origin providing the dopaminergic innervation of the hippocampus. J Hirnforsch 1984;25:1-10.
15. Verney C, Baulac M, Berger B, Alvarez C, Vigny A, Helle KB. Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat. Neuroscience 1985;14:1039-52. PMID: 2860616
crossref pmid
16. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170-97. PMID: 6841683
crossref pmid
17. Köhler C. Morphological details of the projection from the presubiculum to the entorhinal area as shown with the novel PHA-L immunohistochemical tracing method in the rat. Neurosci Lett 1984;45:285-90. PMID: 6374516
crossref pmid
18. Chan-Palay V, Köhler C, Haesler U, Lang W, Yasargil G. Distribution of neurons and axons immunoreactive with antisera against neuropeptide Y in the normal human hippocampus. J Comp Neurol 1986;248:360-75. PMID: 3522662
crossref pmid pdf
19. Becquet D, Faudon M, Hery F. In vivo evidence for an inhibitory glutamatergic control of serotonin release in the cat caudate nucleus: involvement of GABA neurons. Brain Res 1990;519:82-8. PMID: 1975768
crossref pmid
20. Yoshioka M, Matsumoto M, Togashi H, Smith CB, Saito H. Effect of clonidine on the release of serotonin from the rat hippocampus as measured by microdialysis. Neurosci Lett 1992;139:57-60. PMID: 1383883
crossref pmid
21. Tao R, Hjorth S. Alpha 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn Schmiedebergs Arch Pharmacol 1992;345:137-43. PMID: 1349158
pmid
22. Yoshioka M, Matsumoto M, Togashi H, Smith CB, Saito H. Opioid receptor regulation of 5-hydroxytryptamine release from the rat hippocampus measured by in vivo microdialysis. Brain Res 1993;613:74-9. PMID: 8394180
crossref pmid
23. Maura G, Fedele E, Raiteri M. Acetylcholine release from rat hippocampal slices is modulated by 5-hydroxytryptamine. Eur J Pharmacol 1989;165:173-9. PMID: 2528465
crossref pmid
24. Done CJ, Sharp T. Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol 1992;107:240-5. PMID: 1422575
crossref pmid pmc
25. Ropert N, Guy N. Serotonin facilitates GABAergic transmission in the CA1 region of rat hippocampus in vitro. J Physiol 1991;441:121-36. PMID: 1687746
crossref pmid pmc
26. Greenamyre JT, Young AB, Penney JB. Quantitative autoradiography of L-[3H]glutamate binding to rat brain. Neurosci Lett 1983;37:155-60. PMID: 6136011
crossref pmid
27. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43:1369-74. PMID: 6149259
crossref pmid
28. Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of Nmethyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984;226:850-2. PMID: 6093256
crossref pmid
29. Bose B, Osterholm JL, Triolo A. Focal cerebral ischemia: reduction in size of infarcts by ventriculo-subarachnoid perfusion with fluorocarbon emulsion. Brain Res 1985;328:223-31. PMID: 3157423
crossref pmid
30. Drejer J, Benveniste H, Diemer NH, Schousboe A. Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro. J Neurochem 1985;45:145-51. PMID: 2860206
crossref pmid
31. Silverstein FS, Buchanan K, Johnston MV. Perinatal hypoxia-ischemia disrupts striatal high-affinity [3H]glutamate uptake into synaptosomes. J Neurochem 1986;47:1614-9. PMID: 2876058
crossref pmid
32. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor--still lethal after eight years. Trends Neurosci 1995;18:57-8. PMID: 7537407
crossref pmid
33. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 1988;24:543-51. PMID: 2853604
crossref pmid
34. Graham SH, Chen J, Sharp FR, Simon RP. Limiting ischemic injury by inhibition of excitatory amino acid release. J Cereb Blood Flow Metab 1993;13:88-97. PMID: 8093250
crossref pmid pdf
35. Kumami K, Yamamoto T, Villacara A, Mrsulja BB, Spatz M. Ischemic cerebral edema. 5-hydroxytryptamine receptors and the physical state of synaptosomal membranes. Adv Neurol 1990;52:47-56. PMID: 2204256
pmid
36. Globus MY, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis. J Neurochem 1988;51:1455-64. PMID: 2902196
pmid
37. Globus MY, Wester P, Busto R, Dietrich WD. Ischemia-induced extracellular release of serotonin plays a role in CA1 neuronal cell death in rats. Stroke 1992;23:1595-601. crossref
38. Koide T, Wieloch TW, Siesjö BK. Circulating catecholamines modulate ischemic brain damage. J Cereb Blood Flow Metab 1986;6:559-65. PMID: 2876001
crossref pmid pdf
39. Globus MY, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. Intra-ischemic extracellular release of dopamine and glutamate is associated with striatal vulnerability to ischemia. Neurosci Lett 1988;91:36-40. PMID: 2902538
crossref pmid
40. Lehmann J, Scatton B. Characterization of the excitatory amino acid receptor-mediated release of [3H]acetylcholine from rat striatal slices. Brain Res 1982;252:77-89. PMID: 6129033
crossref pmid
41. Chang HY, Cheng CL, Chen JJ, de Groat WC. Roles of glutamatergic and serotonergic mechanisms in reflex control of the external urethral sphincter in urethane-anesthetized female rats. Am J Physiol Regul Integr Comp Physiol 2006;291:R224-34. PMID: 16469836
crossref pmid
42. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001;41:691-721. PMID: 11264473
crossref pmid
43. Yoshiyama M, de Groat WC. Supraspinal and spinal alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and N-methyl-Daspartate glutamatergic control of the micturition reflex in the urethane-anesthetized rat. Neuroscience 2005;132:1017-26. PMID: 15857706
crossref pmid pmc
44. de Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Compr Physiol 2015;5:327-96. PMID: 25589273
crossref pmid pmc pdf
45. Tadic SD, Tannenbaum C, Resnick NM, Griffiths D. Brain responses to bladder filling in older women without urgency incontinence. Neurourol Urodyn 2013;32:435-40. PMID: 23475745
crossref pmid pmc pdf
46. Kim JH, Ahn YS, Song YS. Serotonin discharge regulation by additional neurotransmitters of rat hippocampus associated with the continence central circuit. Int Neurourol J 2021;25(Suppl 2):S106-13. PMID: 34844393
crossref pmid pmc pdf
47. Garraway SM, Hochman S. Modulatory actions of serotonin, norepinephrine, dopamine, and acetylcholine in spinal cord deep dorsal horn neurons. J Neurophysiol 2001;86:2183-94. PMID: 11698510
crossref pmid
48. Kim JH, Ahn YS, Song YS. Liberation of serotonin is not unaffected by acetylcholine in rat hippocampus. Int Neurourol J 2021;25(Suppl 2):S114-9. PMID: 34844394
crossref pmid pmc pdf

Fig. 1.
Spontaneous release of [3H]5-HT. [3H]5-HT showed a high initial efflux that gradually declined over the first 30–40 minutes and stabilized plateau by 50 minutes. Values are expressed as mean±standard error of the mean. 5-HT, serotonin.
inj-2550346-173f1.jpg
Fig. 2.
Time course of [3H]5-HT release from rat hippocampal slices in response to different neurotransmitters. (A) Norepinephrine (10–5M) significantly increased serotonin (5-HT) release compared with control, and this effect persisted in the presence of tetrodotoxin (TTX), indicating a direct action on serotonergic terminals. (B) Dopamine (10–5M) produced a robust and sustained enhancement of 5-HT release, also unaffected by TTX. (C) N-methyl-D-aspartate (NMDA, 10–4M) transiently increased 5-HT release; however, this effect was completely abolished by TTX, consistent with an interneuron-dependent mechanism. Values are expressed as mean±standard error of the mean. *P<0.05 for NMDA-alone versus control. #P<0.05 for NMDA versus NMDA+TTX.
inj-2550346-173f2.jpg
Fig. 3.
Time course of [3H]5-HT release from rat hippocampal slices in response to different neurotransmitters. (A) Effects of acetylcholine (10–5M), (B) gamma-aminobutyric acid (GABA, 10–5M), (C) glycine (10–5M), and (D) neuropeptide Y (10–6M) on hippocampal serotonin (5-HT) release. None of these neurotransmitters significantly altered 5-HT output relative to control slices. Responses were unchanged in the presence or absence of tetrodotoxin, indicating no direct or indirect acute modulation of serotonergic release by these transmitters under the tested conditions. Values are expressed as mean±standard error of the mean.
inj-2550346-173f3.jpg
TOOLS
Share :
Facebook Twitter Linked In Google+
METRICS Graph View
  • 0 Crossref
  • 0 Scopus
  • 770 View
  • 24 Download
We recommend


ARTICLE & ORGAN
Article Category

Browse all articles >

Organ

Browse all articles >

ISSUES
DISEASES & TOPICS
Diseases

Browse all articles >

Topics

Browse all articles >

AUTHOR
INFORMATION

Official Journal of Korean Society of Functional and Reconstructive Urology & ESSIC (International Society for the Study of BPS) & Korean Society of Urological Research & The Korean Children’s Continence and Enuresis Society & The Korean Association of Urogenital Tract Infection and Inflammation & Korean Society of Geriatric Urological Care
Editorial Office
Department of Urology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine,
29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea
Tel: +82-2-2001-2237     Fax: +82-2-2001-2247    E-mail: support@einj.org

Copyright © 2026 by Korean Society of Functional and Reconstructive Urology.

Developed in M2PI

Close layer
prev next